艾塞那肽联合枸橼酸氯米芬治疗多囊卵巢综合征伴胰岛素抵抗的临床观察

发布时间：2018-04-25 03:37

本文选题：艾塞那肽 + 二甲双胍　；参考：《中国药房》2017年12期

【摘要】：目的 :观察艾塞那肽联合枸橼酸氯米芬治疗多囊卵巢综合征伴胰岛素抵抗的疗效和安全性。方法:98例多囊卵巢综合征伴胰岛素抵抗患者随机分为对照组(49例)和观察组(49例)。对照组患者给予枸橼酸氯米芬胶囊50 mg,口服,每日1次,连用5d+二甲双胍肠溶片首次剂量0.25 g,口服,每日2次,后调整剂量至0.50~0.75 g,口服,每日2次,连用3个月经周期。观察组患者给予枸橼酸氯米芬胶囊(用法用量同对照组)+艾塞那肽注射液5μg,每日2次,皮下注射1个月,后调整剂量至10μg,每日2次,皮下注射2个月。观察两组患者的临床疗效,治疗前后促黄体生成素(LH)、促卵泡激素(FSH)、LH/FSH和胰岛素抵抗指数(IR),不孕患者治疗后排卵及妊娠情况,并记录不良反应发生情况。结果:观察组患者总有效率、排卵率、妊娠率均显著高于对照组,差异均有统计学意义(P0.05)。治疗前,两组患者LH、FSH、LH/FSH和IR比较,差异均无统计学意义(P0.05)。治疗后,两组患者LH、LH/FSH、IR均显著低于同组治疗前,且观察组显著低于对照组;两组患者FSH均显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:艾塞那肽联合枸橼酸氯米芬治疗多囊卵巢综合征伴胰岛素抵抗的疗效显著,可通过改善胰岛素抵抗来提高排卵率及妊娠率,且未增加不良反应的发生。
[Abstract]:Aim: to observe the efficacy and safety of ixanapeptide combined with clomiphene citrate in the treatment of polycystic ovary syndrome with insulin resistance. Methods Ninety-eight patients with polycystic ovary syndrome with insulin resistance were randomly divided into control group (n = 49) and observation group (n = 49). In the control group, 50 mg clomiphene citrate capsule was given orally, once a day, the first dose of metformin enteric-coated tablets was 0.25 g for 5 days, twice a day, and the adjusted dose was 0.50 ~ 0.75 g, orally, twice a day, for 3 consecutive menstrual cycles. The patients in the observation group were given clomiphene citrate capsule (dosage the same as the control group) 5 渭 g, twice a day, subcutaneously for 1 month, then adjusted to 10 渭 g, twice a day, subcutaneously for 2 months. The clinical effects of the two groups were observed, including luteinizing hormone (LHN), follicle stimulating hormone (FSH), LH / FSH and insulin resistance index (IRI) before and after treatment. Ovulation and pregnancy were recorded in infertile patients after treatment, and adverse reactions were recorded. Results: the total effective rate, ovulation rate and pregnancy rate in the observation group were significantly higher than those in the control group (P 0.05). Before treatment, there was no significant difference in LHH / FSH and IR between the two groups. After treatment, the FSH of the two groups was significantly lower than that of the control group, and the FSH of the observation group was significantly higher than that of the control group, and that of the observation group was significantly higher than that of the control group (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: Isenapeptide combined with clomiphene citrate is effective in the treatment of polycystic ovary syndrome with insulin resistance. It can improve the ovulation rate and pregnancy rate by improving insulin resistance and does not increase the occurrence of adverse reactions.
【作者单位】：湖北中医药大学黄家湖医院妇科;
【基金】：中国博士后科学基金资助项目(No.2013M542498)
【分类号】：R711.75

【相似文献】